Skip to main content
. 2016 Feb;7(1):122–128. doi: 10.3978/j.issn.2078-6891.2015.099

Table S1. Annual burden of patients in the United States eligible for consideration of CRS + HIPEC.

Primary tumor Estimated new cases per year % of peritoneal metastases Estimated new cases of peritoneal metastases per year
Colorectal carcinoma 132,700 (39) 8-17% (40,41) 10,620-22,550
Appendiceal carcinoma 1,500 40% 600
Gastric carcinoma 24,590 (39) 20% 4,920
Ovarian carcinoma 21,290 (39) 60% (42) 12,770
Peritoneal mesothelioma 350 (43) 100% 350

CRS, cytoreductive surgery; HIPEC, hyperthermic intra-peritoneal chemoperfusion.